



CHOICESM
Health Plans

VNSNY CHOICE Total Step Therapy Requirements

Effective: 05/01/2019

AMANTADINE ER

Products Affected

Step 2:

- OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 258 MG TABLET, EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS.
-----------------	--

ANTIDIABETIC AGENTS - MISCELLANEOUS

Products Affected

Step 2:

- GLYXAMBI 10 MG-5 MG TABLET
- GLYXAMBI 25 MG-5 MG TABLET
- INVOKAMET 150 MG-1,000 MG TABLET
- INVOKAMET 150 MG-500 MG TABLET
- INVOKAMET 50 MG-1,000 MG TABLET
- INVOKAMET 50 MG-500 MG TABLET
- INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKANA 100 MG TABLET
- INVOKANA 300 MG TABLET
- JARDIANCE 10 MG TABLET
- JARDIANCE 25 MG TABLET
- SYNJARDY 12.5 MG-1,000 MG TABLET
- SYNJARDY 12.5 MG-500 MG TABLET
- SYNJARDY 5 MG-1,000 MG TABLET
- SYNJARDY 5 MG-500 MG TABLET
- SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR METFORMIN, METFORMIN ER, A SULFONYLUREA AGENT (GLYBURIDE, GLIPIZIDE, GLIMEPIRIDE, TOLAZAMIDE), PIOGLITAZONE, OR COMBINATION OF A SULFONYLUREA-METFORMIN WITHIN THE PAST 120 DAYS.
-----------------	---

ANTI-INFLAMMATORY AGENTS - GI

Products Affected

Step 2:

- DIPENTUM 250 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR ANY 1 OF THE FOLLOWING: BALSALAZIDE, APRISO, DELZICOL, MESALAMINE DR 800 MG TAB, OR FORMULARY MESALAMINE 1.2 G DR TAB WITHIN THE PAST 120 DAYS.
-----------------	--

ANTIPSYCHOTIC AGENTS

Products Affected

Step 2:

- *aripiprazole 10 mg disintegrating tablet*
- *aripiprazole 15 mg disintegrating tablet*
- *clozapine 100 mg disintegrating tablet*
- *clozapine 12.5 mg disintegrating tablet*
- *clozapine 150 mg disintegrating tablet*
- *clozapine 200 mg disintegrating tablet*
- *clozapine 25 mg disintegrating tablet*
- FANAPT 1 MG TABLET
- FANAPT 10 MG TABLET
- FANAPT 12 MG TABLET
- FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK
- FANAPT 2 MG TABLET
- FANAPT 4 MG TABLET
- FANAPT 6 MG TABLET
- FANAPT 8 MG TABLET
- SAPHRIS 10 MG SUBLINGUAL TABLET
- SAPHRIS 2.5 MG SUBLINGUAL TABLET
- SAPHRIS 5 MG SUBLINGUAL TABLET
- VERSACLOZ 50 MG/ML ORAL SUSPENSION
- VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK
- VRAYLAR 1.5 MG CAPSULE
- VRAYLAR 3 MG CAPSULE
- VRAYLAR 4.5 MG CAPSULE
- VRAYLAR 6 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSIONS OF ANY TWO ORAL ANTIPSYCHOTICS: RISPERIDONE, CLOZAPINE TABLET, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE WITHIN THE PAST 365 DAYS.
-----------------	--

ANTIPSYCHOTIC AGENTS II

Products Affected

Step 2:

- REXULTI 0.25 MG TABLET
- REXULTI 0.5 MG TABLET
- REXULTI 1 MG TABLET
- REXULTI 2 MG TABLET
- REXULTI 3 MG TABLET
- REXULTI 4 MG TABLET

Details

Criteria	PRIOR CLAIM FOR TWO (2) OF THE FOLLOWING FORMULARY ORAL VERSIONS OF ATYPICAL ANTIPSYCHOTICS (RISPERIDONE, CLOZAPINE, OLANZAPINE, QUETIAPINE, ARIPIPRAZOLE OR ZIPRASIDONE) OR SSRI (CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE OR SERTRALINE) OR SNRI (DESVENLAFAXINE, DULOXETINE OR VENLAFAXINE) WITHIN THE PAST 365 DAYS
----------	---

ANTIULCER AGENTS

Products Affected

Step 2:

- DEXILANT 30 MG CAPSULE, DELAYED RELEASE
- DEXILANT 60 MG CAPSULE, DELAYED RELEASE
- *rabeprazole 20 mg tablet, delayed release*

Details

Criteria	PRIOR CLAIM FOR GENERIC FEDERAL LEGEND ORAL OMEPRAZOLE, PANTOPRAZOLE, OR LANSOPRAZOLE WITHIN THE PAST 120 DAYS.
----------	---

B VERSUS D ADMINISTRATIVE STEP

Products Affected

Step 2:

- CYCLOPHOSPHAMIDE 25 MG CAPSULE
- CYCLOPHOSPHAMIDE 50 MG CAPSULE
- *methotrexate sodium 2.5 mg tablet*
- XATMEP 2.5 MG/ML ORAL SOLUTION

Details

Criteria	IN ORDER TO ASSIST IN A PART B VS. D PAYMENT DETERMINATION, A PRIOR CLAIM SEEN FOR A RHEUMATOID ARTHRITIS, PSORIASIS OR ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG WITHIN THE PAST 120 DAYS WILL QUALIFY FOR PART D PAYMENT. ALL OTHER INDICATIONS WILL HAVE A PART B VS. D PAYMENT DETERMINATION MADE THROUGH THE FORMULARY EXCEPTION PROCESS PRIOR TO THE APPROVAL OF THE DRUG.
----------	--

ELUXADOLINE

Products Affected

Step 2:

- VIBERZI 100 MG TABLET
- VIBERZI 75 MG TABLET

Details

Criteria	PRIOR CLAIM FOR DICYCLOMINE AND XIFAXAN 550MG WITHIN THE PAST 365 DAYS.
-----------------	---

FIDAXOMICIN

Products Affected

Step 2:

- DIFICID 200 MG TABLET

Details

Criteria	PRIOR CLAIM FOR ORAL VANCOMYCIN IN THE PAST 120 DAYS.
-----------------	---

GABAPENTIN SR

Products Affected

Step 2:

- GRALISE 300 MG
TABLET,EXTENDED RELEASE
- GRALISE 30-DAY STARTER PACK
300 MG (9)-600 MG (69) TABLET,EXT.
- GRALISE 600 MG
TABLET,EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR GABAPENTIN IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS.
-----------------	--

INSULIN/GLP-1 ANALOG

Products Affected

Step 2:

- SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN
- XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN

Details

Criteria	PRIOR CLAIM FOR 2 OF THE FOLLOWING (ONE FROM EACH GROUP): A) VICTOZA, LANTUS, TOUJEO, OR OZEMPIC AND B) METFORMIN, METFORMIN ER, SULFONYLUREA AGENT (GLYBURIDE, GLIPIZIDE, GLIMEPIRIDE, TOLAZAMIDE), COMBO SULFONYLUREA-METFORMIN, OR PIOGLITAZONE IN PAST 365 DAYS.
----------	--

NOVEL ORAL ANTICOAGULANTS

Products Affected

Step 2:

- PRADAXA 110 MG CAPSULE
- PRADAXA 150 MG CAPSULE
- PRADAXA 75 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR ELIQUIS AND XARELTO IN THE PAST 365 DAYS.
-----------------	---

OPHTHALMIC ANTIHISTAMINES

Products Affected

Step 2:

- ALREX 0.2 % EYE DROPS,SUSPENSION
- BEPREVE 1.5 % EYE DROPS

Details

Criteria	PRIOR CLAIM FOR ONE OF THE FOLLOWING: OTC LORATADINE, OTC LORATADINE D, OTC CETIRIZINE, OTC CETIRIZINE D, OTC FEXOFENADINE, OTC FEXOFENADINE D, OTC LEVOCETIRIZINE, OTC GENERIC KETOTIFEN EYE DROPS 0.025%, LEVOCETIRIZINE, CROMOLYN SODIUM, EPINASTINE, OR FORMULARY OLOPATADINE EYE DROPS WITHIN THE PAST 120 DAYS.
-----------------	---

SPRITAM

Products Affected

Step 2:

- SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 250 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 500 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 750 MG TABLET FOR ORAL SUSPENSION

Details

Criteria	PRIOR CLAIM FOR LEVETIRACETAM SOLUTION IN THE PAST 120 DAYS
-----------------	---

INDEX

ALREX 0.2 % EYE DROPS,SUSPENSION.....	13	INVOKAMET 50 MG-500 MG TABLET.....	2
<i>aripiprazole 10 mg disintegrating tablet</i>	4	INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE.....	2
<i>aripiprazole 15 mg disintegrating tablet</i>	4	INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE.....	2
BEPREVE 1.5 % EYE DROPS.....	13	INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE.....	2
<i>clozapine 100 mg disintegrating tablet</i>	4	INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE.....	2
<i>clozapine 12.5 mg disintegrating tablet</i>	4	INVOKANA 100 MG TABLET.....	2
<i>clozapine 150 mg disintegrating tablet</i>	4	INVOKANA 300 MG TABLET.....	2
<i>clozapine 200 mg disintegrating tablet</i>	4	JARDIANCE 10 MG TABLET.....	2
<i>clozapine 25 mg disintegrating tablet</i>	4	JARDIANCE 25 MG TABLET.....	2
CYCLOPHOSPHAMIDE 25 MG CAPSULE.....	7	<i>methotrexate sodium 2.5 mg tablet</i>	7
CYCLOPHOSPHAMIDE 50 MG CAPSULE.....	7	OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE.....	1
DEXILANT 30 MG CAPSULE, DELAYED RELEASE.....	6	OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE.....	1
DEXILANT 60 MG CAPSULE, DELAYED RELEASE.....	6	OSMOLEX ER 258 MG TABLET, EXTENDED RELEASE.....	1
DIFICID 200 MG TABLET.....	9	PRADAXA 110 MG CAPSULE.....	12
DIPENTUM 250 MG CAPSULE.....	3	PRADAXA 150 MG CAPSULE.....	12
FANAPT 1 MG TABLET.....	4	PRADAXA 75 MG CAPSULE.....	12
FANAPT 10 MG TABLET.....	4	<i>rabeprazole 20 mg tablet, delayed release</i>	6
FANAPT 12 MG TABLET.....	4	REXULTI 0.25 MG TABLET.....	5
FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK.....	4	REXULTI 0.5 MG TABLET.....	5
FANAPT 2 MG TABLET.....	4	REXULTI 1 MG TABLET.....	5
FANAPT 4 MG TABLET.....	4	REXULTI 2 MG TABLET.....	5
FANAPT 6 MG TABLET.....	4	REXULTI 3 MG TABLET.....	5
FANAPT 8 MG TABLET.....	4	REXULTI 4 MG TABLET.....	5
GLYXAMBI 10 MG-5 MG TABLET.....	2	SAPHRIS 10 MG SUBLINGUAL TABLET.....	4
GLYXAMBI 25 MG-5 MG TABLET.....	2	SAPHRIS 2.5 MG SUBLINGUAL TABLET.....	4
GRALISE 300 MG TABLET,EXTENDED RELEASE.....	10	SAPHRIS 5 MG SUBLINGUAL TABLET.....	4
GRALISE 30-DAY STARTER PACK 300 MG (9)-600 MG (69) TABLET,EXT. RELEASE.....	10	SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS	
GRALISE 600 MG TABLET,EXTENDED RELEASE.....	10	INSULIN PEN.....	11
INVOKAMET 150 MG-1,000 MG TABLET.....	2	SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION.....	15
INVOKAMET 150 MG-500 MG TABLET.....	2	SPRITAM 250 MG TABLET FOR ORAL SUSPENSION.....	15
INVOKAMET 50 MG-1,000 MG TABLET.....	2		

SPRITAM 500 MG TABLET FOR ORAL SUSPENSION.....	15
SPRITAM 750 MG TABLET FOR ORAL SUSPENSION.....	15
SYNJARDY 12.5 MG-1,000 MG TABLET.....	2
SYNJARDY 12.5 MG-500 MG TABLET.....	2
SYNJARDY 5 MG-1,000 MG TABLET.....	2
SYNJARDY 5 MG-500 MG TABLET.....	2
SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE.....	2
SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE.....	2
SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE.....	2
SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE.....	2
TEKTURNA 150 MG TABLET.....	14
TEKTURNA 300 MG TABLET.....	14
TEKTURNA HCT 150 MG-12.5 MG TABLET.....	14
TEKTURNA HCT 150 MG-25 MG TABLET.....	14
TEKTURNA HCT 300 MG-12.5 MG TABLET.....	14
TEKTURNA HCT 300 MG-25 MG TABLET.....	14
VERSACLOZ 50 MG/ML ORAL SUSPENSION.....	4
VIBERZI 100 MG TABLET.....	8
VIBERZI 75 MG TABLET.....	8
VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK.....	4
VRAYLAR 1.5 MG CAPSULE.....	4
VRAYLAR 3 MG CAPSULE.....	4
VRAYLAR 4.5 MG CAPSULE.....	4
VRAYLAR 6 MG CAPSULE.....	4
XATMEP 2.5 MG/ML ORAL SOLUTION.....	7
XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN.....	11